» Articles » PMID: 28566998

Relative Contribution of Prolyl Hydroxylase-Dependent and -Independent Degradation of HIF-1alpha by Proteasomal Pathways in Cerebral Ischemia

Overview
Journal Front Neurosci
Date 2017 Jun 2
PMID 28566998
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Hypoxia inducible factor-1 (HIF-1) is a key regulator in hypoxia and can determine the fate of brain cells during ischemia. However, the mechanism of HIF-1 regulation is still not fully understood in ischemic brains. We tested a hypothesis that both the 26S and the 20S proteasomal pathways were involved in HIF-1α degradation under ischemic conditions. Using ischemic model (oxygen and glucose deprivation) and a mouse model of middle cerebral artery occlusion, we tested effects of inhibitors of proteasomes and prolyl hydroxylase (PHD) on HIF-1α stability and brain injury in cerebral ischemia. We observed that 30 and 60 min of oxygen-glucose deprivation significantly increased the 20S proteasomal activity. We demonstrated that proteasome inhibitors increased HIF-1α stabilization and cell viability and were more effective than PHD inhibitors in primary cultured cortical neurons exposed to oxygen and glucose deprivation. Furthermore, the administration of the proteasome inhibitor, epoxomicin, to mice resulted in smaller infarct size and brain edema than a PHD inhibitor. Our results indicate that 20S proteasomes are involved in HIF-1α degradation in ischemic neurons and that proteasomal inhibition provides more HIF-1α stabilization and neuroprotection than PHD inhibition in cerebral ischemia.

Citing Articles

Physiological and cellular mechanisms of ischemic preconditioning microRNAs-mediated in underlying of ischemia/reperfusion injury in different organs.

Gheitasi I, Akbari G, Savari F Mol Cell Biochem. 2024; 480(2):855-868.

PMID: 39001984 DOI: 10.1007/s11010-024-05052-7.


Transcriptional Modulation Reveals Physiological Responses to Temperature Adaptation in .

Wei Z, Fang Y, Shi W, Chu Z, Zhao B Int J Mol Sci. 2023; 24(14).

PMID: 37511383 PMC: 10380296. DOI: 10.3390/ijms241411622.


Epigenetic Reprogramming via Synergistic Hypomethylation and Hypoxia Enhances the Therapeutic Efficacy of Mesenchymal Stem Cell Extracellular Vesicles for Bone Repair.

Man K, Brunet M, Lees R, Peacock B, Cox S Int J Mol Sci. 2023; 24(8).

PMID: 37108726 PMC: 10142722. DOI: 10.3390/ijms24087564.


Exploration on the Mechanism of Ubiquitin Proteasome System in Cerebral Stroke.

Li Y, Wang Y, Zou W Front Aging Neurosci. 2022; 14:814463.

PMID: 35462700 PMC: 9022456. DOI: 10.3389/fnagi.2022.814463.


Hypoxic modulation of fetal vascular MLCK abundance, localization, and function.

Sorensen D, Carreon D, Williams J, Pearce W Am J Physiol Regul Integr Comp Physiol. 2020; 320(1):R1-R18.

PMID: 33112654 PMC: 7847055. DOI: 10.1152/ajpregu.00212.2020.


References
1.
Sorond F, Tan C, LaRose S, Monk A, Fichorova R, Ryan S . Deferoxamine, Cerebrovascular Hemodynamics, and Vascular Aging: Potential Role for Hypoxia-Inducible Transcription Factor-1-Regulated Pathways. Stroke. 2015; 46(9):2576-83. PMC: 4551113. DOI: 10.1161/STROKEAHA.115.009906. View

2.
Giaccia A, Siim B, Johnson R . HIF-1 as a target for drug development. Nat Rev Drug Discov. 2003; 2(10):803-11. DOI: 10.1038/nrd1199. View

3.
Yan J, Zhou B, Taheri S, Shi H . Differential effects of HIF-1 inhibition by YC-1 on the overall outcome and blood-brain barrier damage in a rat model of ischemic stroke. PLoS One. 2011; 6(11):e27798. PMC: 3218033. DOI: 10.1371/journal.pone.0027798. View

4.
Fekete M, McBride W, Pajonk F . Anthracyclines, proteasome activity and multi-drug-resistance. BMC Cancer. 2005; 5:114. PMC: 1242219. DOI: 10.1186/1471-2407-5-114. View

5.
Siddiq A, Ayoub I, Chavez J, Aminova L, Shah S, LaManna J . Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem. 2005; 280(50):41732-43. PMC: 2586128. DOI: 10.1074/jbc.M504963200. View